TY - JOUR
T1 - The impact of age and gender on papillary thyroid cancer survival
AU - Jonklaas, Jacqueline
AU - Nogueras-Gonzalez, G.
AU - Munsell, M.
AU - Litofsky, D.
AU - Ain, K. B.
AU - Bigos, S. T.
AU - Brierley, J. D.
AU - Cooper, D. S.
AU - Haugen, B. R.
AU - Ladenson, P. W.
AU - Magner, J.
AU - Robbins, J.
AU - Ross, D. S.
AU - Skarulis, M. C.
AU - Steward, D. L.
AU - Maxon, H. R.
AU - Sherman, S. I.
PY - 2012/6
Y1 - 2012/6
N2 - Context: Thyroid cancer predominately affects women, carries a worse prognosis in older age, and may have higher mortality in men. Superimposed on these observations is the fact that most women have attained menopause by age 55 yr. Objective: The objective of the study was to determine whether men contribute disproportionately to papillary thyroid cancer (PTC) mortality or whether menopause affects PTC prognosis. Design: Gender-specific mortality was normalized using age-matched subjects from the U.S. population. Multivariate Cox proportional hazard regression models incorporating gender, age, and National Thyroid Cancer Treatment Cooperative Study Group stage were used to model disease-specific survival (DSS). Participants and Setting: Patients were followed in a prospective registry. Main Outcome Measure: The relationships between gender, age, and PTC outcomes were analyzed. Results: The unadjusted hazard ratio (HR) for DSS for women was 0.40 [confidence interval (CI) 0.24-0.65]. This female advantage diminished when DSS was adjusted for age at diagnosis and stage with a HR encompassing unity (HR0.72, CI0.44-1.19). Additional multivariate models of DSS considering gender, disease stage, and various age groupings showed that the DSS for women diagnosed at under 55 yr was improved over men (HR 0.33, CI 0.13-0.81). However, the HR for DSS increased to become similar to men for women diagnosed at 55-69 yr (HR 1.01, CI 0.42-2.37) and at 70 yr or greater (HR 1.17, CI 0.48-2.85). Conclusions: Although the overall outcome of women with PTC is similar to men, subgroup analysis showed that this composite outcome is composed of two periods with different outcomes. The first period is a period with better outcomes for women than men when the diagnosis occurs at younger than 55 yr; the second is a period with similar outcomes for both women and men diagnosed at ages greater than 55 yr. These data raise the question of whether an older age cut off would improve current staging systems. We hypothesize that older age modifies the effect of gender on outcomes due to menopause-associated hormonal alterations.
AB - Context: Thyroid cancer predominately affects women, carries a worse prognosis in older age, and may have higher mortality in men. Superimposed on these observations is the fact that most women have attained menopause by age 55 yr. Objective: The objective of the study was to determine whether men contribute disproportionately to papillary thyroid cancer (PTC) mortality or whether menopause affects PTC prognosis. Design: Gender-specific mortality was normalized using age-matched subjects from the U.S. population. Multivariate Cox proportional hazard regression models incorporating gender, age, and National Thyroid Cancer Treatment Cooperative Study Group stage were used to model disease-specific survival (DSS). Participants and Setting: Patients were followed in a prospective registry. Main Outcome Measure: The relationships between gender, age, and PTC outcomes were analyzed. Results: The unadjusted hazard ratio (HR) for DSS for women was 0.40 [confidence interval (CI) 0.24-0.65]. This female advantage diminished when DSS was adjusted for age at diagnosis and stage with a HR encompassing unity (HR0.72, CI0.44-1.19). Additional multivariate models of DSS considering gender, disease stage, and various age groupings showed that the DSS for women diagnosed at under 55 yr was improved over men (HR 0.33, CI 0.13-0.81). However, the HR for DSS increased to become similar to men for women diagnosed at 55-69 yr (HR 1.01, CI 0.42-2.37) and at 70 yr or greater (HR 1.17, CI 0.48-2.85). Conclusions: Although the overall outcome of women with PTC is similar to men, subgroup analysis showed that this composite outcome is composed of two periods with different outcomes. The first period is a period with better outcomes for women than men when the diagnosis occurs at younger than 55 yr; the second is a period with similar outcomes for both women and men diagnosed at ages greater than 55 yr. These data raise the question of whether an older age cut off would improve current staging systems. We hypothesize that older age modifies the effect of gender on outcomes due to menopause-associated hormonal alterations.
UR - http://www.scopus.com/inward/record.url?scp=84861996314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861996314&partnerID=8YFLogxK
U2 - 10.1210/jc.2011-2864
DO - 10.1210/jc.2011-2864
M3 - Article
C2 - 22496497
AN - SCOPUS:84861996314
SN - 0021-972X
VL - 97
SP - E878-E887
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 6
ER -